Anavex Life Sciences Corp (AVXL)

[sokol]

I believe it would be a mistake to attempt to license this drug, AVXL 2-73 (that includes its metabolite 19-144) for a single indication when it has potential for many indications. Remember too that such an attempt must also take into consideration the issue of off label prescribing that doctors are allowed to do. Instead, I believe that the multiple indications of Anavex’s drugs adds value that must be taken into consideration when negotiating a partnership for future development and marketing of Anavex’s drugs. Multiple indications are valuable. Additionally, Orphan drugs have value because Orphan drugs can be used with tremendous success in extending the life cycle of Anavex’s drugs. For example, see this:

''Orphan drug companies have used with tremendous success as part of their drug life cycle management, the strategy to extend the life of their product by devising a succession of multiple discrete indications for the orphan drug. This strategy is critical to the continued financial success for orphan drug companies, especially when facing the challenges of generic competition and the demise of the traditional blockbuster drug strategy. The advantage of using multiple indications is that it allows a company to progressively expand the drug’s market.

This Blog Post presents several biotechnology companies that have used the multiple indication strategy for orphan drugs successfully:

• Alexion Pharmaceuticals’ Soliris

• Celgene’s Revlimid

• Novartis’ Gleevec.''

https://orphandruganaut.wordpress.com/2015/02/18/orphan-drugs-the-power-of-multiple-indications/